Characterizing Molecular and Synaptic Signatures in mouse models of Late-Onset Alzheimer’s Disease Independent of Amyloid and Tau Pathology

Author:

Kotredes Kevin P.,Pandey Ravi S.,Persohn Scott,Elderidge Kierra,Burton Charles P,Miner Ethan W.,Haynes Kathryn A.,Santos Diogo Francisco S.,Williams Sean-Paul,Heaton Nicholas,Ingraham Cynthia M.,Lloyd Christopher,Garceau Dylan,O’Rourke Rita,Herrick Sarah,Rangel-Barajas Claudia,Maharjan Surendra,Wang Nian,Sasner Michael,Lamb Bruce T.,Territo Paul R.,Sukoff Rizzo Stacey J.,Carter Gregory W.ORCID,Howell Gareth R.ORCID,Oblak Adrian L.ORCID

Abstract

Structured AbstractINTRODUCTIONMODEL-AD is creating and distributing novel mouse models with humanized, clinically relevant genetic risk factors to more accurately mimic LOAD than commonly used transgenic models.METHODSWe created the LOAD2 model by combining APOE4, Trem2*R47H, and humanized amyloid-beta. Mice aged up to 24 months were subjected to either a control diet or a high-fat/high-sugar diet (LOAD2+HFD) from two months of age. We assessed disease-relevant outcomes, including in vivo imaging, biomarkers, multi-omics, neuropathology, and behavior.RESULTSBy 18 months, LOAD2+HFD mice exhibited cortical neuron loss, elevated insoluble brain Aβ42, increased plasma NfL, and altered gene/protein expression related to lipid metabolism and synaptic function. In vivo imaging showed age-dependent reductions in brain region volume and neurovascular uncoupling. LOAD2+HFD mice also displayed deficits in acquiring touchscreen-based cognitive tasks.DISCUSSIONCollectively the comprehensive characterization of LOAD2+HFD mice reveal this model as important for preclinical studies that target features of LOAD independent of amyloid and tau.

Publisher

Cold Spring Harbor Laboratory

Reference98 articles.

1. Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population‐based perspective

2. Neuroinflammation represents a common theme amongst genetic and environmental risk factors for Alzheimer and Parkinson diseases

3. Diet and Alzheimer’s disease risk factors or prevention: the current evidence

4. Biogen . FDA Approves Updated ADUHELM™ Prescribing Information to Emphasize Population Studied in Clinical Trials 2021 [cited 2023 11/21]. Available from: https://investors.biogen.com/news-releases/news-release-details/fda-approves-updated-aduhelmtm-prescribing-information-emphasize.

5. FDA. FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval 2023 [cited 2023 11/21]. Available from: https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval.

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3